{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:39Z","timestamp":1794003879635,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijgc.2026.105598","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:30:37Z","timestamp":1788305437000},"page":"105598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Not all artificial intelligence large language models are created equal: heterogeneous performance in therapeutic decision-making for recurrent epithelial ovarian cancer"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8398-7557","authenticated-orcid":false,"given":"Fulvio","family":"Borella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2374-7030","authenticated-orcid":false,"given":"Stefano","family":"Fucina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Denti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-1201","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Gallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9887-7668","authenticated-orcid":false,"given":"Luca","family":"Bertero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Ditto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-1285","authenticated-orcid":false,"given":"Domenico","family":"Ferraioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2026.105598_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ijgc.2026.105598_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ijgc.2026.105598_bib3","first-page":"436","article-title":"Transforming treatment paradigms: focus on personalized medicine for high-grade serous ovarian cancer","volume":"75","author":"Kordowitzki","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"10.1016\/j.ijgc.2026.105598_bib4","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105598_bib5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2026.105598_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ijgo.70282","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2025 update","volume":"171","author":"Renz","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ijgc.2026.105598_bib7","article-title":"Review of large language models for patient and caregiver support in cancer care delivery","volume":"9","author":"Kouzy","year":"2025","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.ijgc.2026.105598_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/frai.2023.1169595","article-title":"ChatGPT in medicine: an overview of its applications, advantages, limitations, future prospects, and ethical considerations","volume":"6","author":"Dave","year":"2023","journal-title":"Front Artif Intell"},{"key":"10.1016\/j.ijgc.2026.105598_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.semcancer.2023.09.005","article-title":"Artificial intelligence-based risk stratification, accurate diagnosis and treatment prediction in gynecologic oncology","volume":"96","author":"Jiang","year":"2023","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.105598_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MOU.0000000000001272","article-title":"Generative artificial intelligence in oncology","volume":"35","author":"Ganjavi","year":"2025","journal-title":"Curr Opin Urol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.105598_bib11","article-title":"Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery","volume":"9","author":"Bryant","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijgc.2026.105598_bib12","unstructured":"2025 generative AI landscape: the state of Gen AI. Similarweb. Accessed 28 Dec 2025. https:\/\/www.similarweb.com\/corp\/2025-generative-ai-landscape\/."},{"key":"10.1016\/j.ijgc.2026.105598_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2024.07.007","article-title":"ChatGPT compared to national guidelines for management of ovarian cancer: did ChatGPT get it right? - a Memorial Sloan Kettering Cancer Center Team Ovary study","volume":"189","author":"Finch","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105598_bib15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/ijgo.70251","article-title":"Exploring the potential of AI-powered applications for clinical decision-making in gynecologic oncology","volume":"171","author":"Meyer","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ijgc.2026.105598_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ygyno.2023.11.008","article-title":"Let\u2019s chat about cervical cancer: assessing the accuracy of ChatGPT responses to cervical cancer questions","volume":"179","author":"Hermann","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.105598_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/diagnostics16040616","article-title":"Decoding AI competence: benchmarking large language models (LLMs) in ovarian cancer diagnosis and treatment-a systematic evaluation of generative AI accuracy and completeness","volume":"16","author":"Cai","year":"2026","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ijgc.2026.105598_bib18","article-title":"Research progress of artificial intelligence in the early screening, diagnosis, precise treatment and prognosis prediction of three central gynecological malignancies","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"issue":"20","key":"10.1016\/j.ijgc.2026.105598_bib19","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.105598_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.105598_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijgc.2026.105598_bib22","unstructured":"Annex I \u2013 summary of product characteristics (SmPC). European Medicines Agency. Accessed 28 Dec 2025. https:\/\/www.ema.europa.eu\/it\/documents\/product-information\/avastin-epar-product-information_it.pdf."},{"issue":"11","key":"10.1016\/j.ijgc.2026.105598_bib23","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.3390\/ijms21113805","article-title":"Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis","volume":"21","author":"Bartoletti","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ijgc.2026.105598_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001110","article-title":"First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion","volume":"5","author":"Banerjee","year":"2020","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.ijgc.2026.105598_bib25","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.annonc.2023.09.3110","article-title":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO\/ENGOT-ov38): a phase IIIb trial","volume":"34","author":"Pujade-Lauraine","year":"2023","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.105598_bib26","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ijgc.2026.105598_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-025-01686-2","article-title":"Mirvetuximab soravtansine: current and future applications","volume":"18","author":"Kong","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.105598_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104558","article-title":"Natural Language Processing as Consultation Service Platform or Clinical Decision Support System in Gynecologic Oncology: a systematic review","volume":"36","author":"Rosati","year":"2026","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26011291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26011291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:33:51Z","timestamp":1794000831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26011291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1048891X26011291"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.105598","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Not all artificial intelligence large language models are created equal: heterogeneous performance in therapeutic decision-making for recurrent epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.105598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"105598"}}